Can a triple-threat approach wipe out cervical cancer before surgery?
NCT ID NCT07731828
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a short course of radiation combined with the immunotherapy drug adebrelimab and a single platinum chemotherapy drug can eliminate all signs of cancer before surgery in women with locally advanced cervical cancer. Participants receive the combination therapy, then undergo radical hysterectomy. The main goal is to see how many achieve a complete response—no cancer found in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab (an anti-PD-L1 antibody) plus platinum chemotherapy (cisplatin or carboplatin) and short-course radiotherapy
- What this could lead to
- If successful, this combination approach could improve the chance of eliminating all cancer before surgery, potentially leading to better long-term outcomes for women with locally advanced cervical cancer.
- What could go wrong
- This is a small, early-phase trial with only 35 participants and no comparison group, so results may not apply broadly. The combination of radiotherapy, immunotherapy, and chemotherapy may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d predict cervical cancer treatment success?
- Particle beam and immune therapy join forces against cervical cancer
- Dual immunotherapy plus chemo may shrink cervical tumors before surgery
- Protein clues may predict cervical cancer return
- New drug targets hard-to-treat cancers in early trial
- Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?